A dynamic oncology duo team up on an I/O startup focused on next-gen solid tumor fighters

Kyle Blankenship

In the notoriously flighty biotech industry, longtime partnerships aren’t necessarily the norm. But a pair of oncology vets with a history of collaboration apparently likes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A dynamic oncology duo team up on an I/O startup focused on next-gen solid tumor fighters

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A dynamic oncology duo team up on an I/O startup focused on next-gen solid tumor fighters